NASDAQ:EYEN - Eyenovia Stock Price, News & Analysis

$4.17
-0.08 (-1.88 %)
(As of 09/16/2019 02:20 AM ET)
Today's Range
$4.02
Now: $4.17
$4.25
50-Day Range
$3.06
MA: $3.29
$4.21
52-Week Range
$2.40
Now: $4.17
$6.98
Volume32,024 shs
Average Volume45,825 shs
Market Capitalization$68.55 million
P/E RatioN/A
Dividend YieldN/A
Beta1.07
Eyenovia, Inc, a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. It is developing MicroProst, which is in Phase III clinical trials for the treatment of chronic angle closure glaucoma; MicroStat, which is in Phase III clinical trials for the treatment of mydriasis; MicroTears for the treatment of dry eye; and MicroPine for the treatment of myopia. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EYEN
CUSIPN/A
Phone917-289-1117

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.43 per share

Profitability

Net Income$-17,250,000.00

Miscellaneous

EmployeesN/A
Market Cap$68.55 million
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable

Receive EYEN News and Ratings via Email

Sign-up to receive the latest news and ratings for EYEN and its competitors with MarketBeat's FREE daily newsletter.


Eyenovia (NASDAQ:EYEN) Frequently Asked Questions

What is Eyenovia's stock symbol?

Eyenovia trades on the NASDAQ under the ticker symbol "EYEN."

How were Eyenovia's earnings last quarter?

Eyenovia Inc (NASDAQ:EYEN) issued its quarterly earnings data on Monday, August, 12th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.47) by $0.03. View Eyenovia's Earnings History.

When is Eyenovia's next earnings date?

Eyenovia is scheduled to release their next quarterly earnings announcement on Tuesday, November 12th 2019. View Earnings Estimates for Eyenovia.

What price target have analysts set for EYEN?

2 equities research analysts have issued 1-year price targets for Eyenovia's shares. Their predictions range from $9.00 to $14.00. On average, they anticipate Eyenovia's share price to reach $11.50 in the next year. This suggests a possible upside of 175.8% from the stock's current price. View Analyst Price Targets for Eyenovia.

What is the consensus analysts' recommendation for Eyenovia?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eyenovia in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eyenovia.

What are Wall Street analysts saying about Eyenovia stock?

Here are some recent quotes from research analysts about Eyenovia stock:
  • 1. According to Zacks Investment Research, "Eyenovia, Inc. is a clinical stage biopharmaceutical company which engages in developing therapeutics for the treatment of prominent eye diseases primarily in the United States. Its product portfolio includes MicroProst, MicroStat, MicroTears and MicroPine which are in clinical stage. Eyenovia, Inc. is based in New York. " (8/16/2019)
  • 2. HC Wainwright analysts commented, "Our price target is derived from a market value of the firm at $240M, which includes a discounted cash flow-based asset value for all four micro-dosing products, with a 15% discount rate and 1% terminal growth rate. Probabilities of success assigned are 80%, 75%, 55% and 45% for MicroPine, respectively." (2/14/2019)

Has Eyenovia been receiving favorable news coverage?

Media stories about EYEN stock have been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Eyenovia earned a coverage optimism score of 0.9 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Eyenovia.

Are investors shorting Eyenovia?

Eyenovia saw a increase in short interest during the month of August. As of August 31st, there was short interest totalling 246,300 shares, an increase of 7.5% from the July 31st total of 229,100 shares. Based on an average daily trading volume, of 112,100 shares, the days-to-cover ratio is presently 2.2 days. Currently, 2.9% of the shares of the stock are short sold. View Eyenovia's Current Options Chain.

Who are some of Eyenovia's key competitors?

What other stocks do shareholders of Eyenovia own?

Who are Eyenovia's key executives?

Eyenovia's management team includes the folowing people:
  • Dr. Tsontcho Ianchulev M.P.H., M.D., MPH, CEO, Chief Medical Officer & Director (Age 46)
  • Ms. Jennifer Clasby, VP of Clinical Operations (Age 65)
  • Mr. Luke Clauson, VP of R&D (Age 40)
  • Mr. John P. Gandolfo, CFO & Sec. (Age 58)
  • Mr. Michael M. Rowe, VP of Marketing

When did Eyenovia IPO?

(EYEN) raised $30 million in an initial public offering on Thursday, January 25th 2018. The company issued 2,700,000 shares at $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners​ served as the underwriters for the IPO.

Who are Eyenovia's major shareholders?

Eyenovia's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Uniplan Investment Counsel Inc. (3.31%), Vanguard Group Inc. (0.85%) and Hilltop Holdings Inc. (0.19%). Company insiders that own Eyenovia stock include Charles E Iv Mather, Curt H Labelle, Fredric N Eshelman, John P Gandolfo, Michael M Rowe and Tsontcho Ianchulev. View Institutional Ownership Trends for Eyenovia.

Which major investors are selling Eyenovia stock?

EYEN stock was sold by a variety of institutional investors in the last quarter, including Hilltop Holdings Inc.. View Insider Buying and Selling for Eyenovia.

Which major investors are buying Eyenovia stock?

EYEN stock was acquired by a variety of institutional investors in the last quarter, including Uniplan Investment Counsel Inc. and Vanguard Group Inc.. Company insiders that have bought Eyenovia stock in the last two years include Charles E Iv Mather, Curt H Labelle, Fredric N Eshelman, John P Gandolfo, Michael M Rowe and Tsontcho Ianchulev. View Insider Buying and Selling for Eyenovia.

How do I buy shares of Eyenovia?

Shares of EYEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Eyenovia's stock price today?

One share of EYEN stock can currently be purchased for approximately $4.17.

How big of a company is Eyenovia?

Eyenovia has a market capitalization of $68.55 million. The company earns $-17,250,000.00 in net income (profit) each year or ($1.82) on an earnings per share basis. View Additional Information About Eyenovia.

What is Eyenovia's official website?

The official website for Eyenovia is http://www.eyenoviabio.com/.

How can I contact Eyenovia?

Eyenovia's mailing address is 295 Madison Avenue Suite 2400, New York NY, 10017. The company can be reached via phone at 917-289-1117 or via email at [email protected]


MarketBeat Community Rating for Eyenovia (NASDAQ EYEN)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  107 (Vote Outperform)
Underperform Votes:  131 (Vote Underperform)
Total Votes:  238
MarketBeat's community ratings are surveys of what our community members think about Eyenovia and other stocks. Vote "Outperform" if you believe EYEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EYEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/16/2019 by MarketBeat.com Staff

Featured Article: Strangles

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel